These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 31340665)

  • 1. Pharmacokinetics-pharmacodynamics of β-lactamase inhibitors: are we missing the target?
    Monogue ML; Nicolau DP
    Expert Rev Anti Infect Ther; 2019 Aug; 17(8):571-582. PubMed ID: 31340665
    [No Abstract]   [Full Text] [Related]  

  • 2. A review of the pharmacokinetics and pharmacodynamics of aztreonam.
    Ramsey C; MacGowan AP
    J Antimicrob Chemother; 2016 Oct; 71(10):2704-12. PubMed ID: 27334663
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel β-lactam-β-lactamase inhibitor combinations: expectations for the treatment of carbapenem-resistant Gram-negative pathogens.
    Karaiskos I; Galani I; Souli M; Giamarellou H
    Expert Opin Drug Metab Toxicol; 2019 Feb; 15(2):133-149. PubMed ID: 30626244
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
    Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA
    Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ceftazidime-Avibactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination for the Treatment of Resistant Gram-negative Organisms.
    Sharma R; Park TE; Moy S
    Clin Ther; 2016 Mar; 38(3):431-44. PubMed ID: 26948862
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and Pharmacodynamics of β-Lactamase Inhibitors.
    Crass RL; Pai MP
    Pharmacotherapy; 2019 Feb; 39(2):182-195. PubMed ID: 30589457
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A resurgence of β-lactamase inhibitor combinations effective against multidrug-resistant Gram-negative pathogens.
    Bush K
    Int J Antimicrob Agents; 2015 Nov; 46(5):483-93. PubMed ID: 26498989
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Focus on ceftazidime-avibactam for optimizing outcomes in complicated intra-abdominal and urinary tract infections.
    Nicolau DP
    Expert Opin Investig Drugs; 2015; 24(9):1261-73. PubMed ID: 26145447
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An update on β-lactamase inhibitor discovery and development.
    Docquier JD; Mangani S
    Drug Resist Updat; 2018 Jan; 36():13-29. PubMed ID: 29499835
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Newer β-Lactam/β-Lactamase inhibitor for multidrug-resistant gram-negative infections: Challenges, implications and surveillance strategy for India.
    Veeraraghavan B; Pragasam AK; Bakthavatchalam YD; Anandan S; Ramasubramanian V; Swaminathan S; Gopalakrishnan R; Soman R; Abraham OC; Ohri VC; Walia K
    Indian J Med Microbiol; 2018; 36(3):334-343. PubMed ID: 30429384
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New β-lactamase inhibitors: a therapeutic renaissance in an MDR world.
    Drawz SM; Papp-Wallace KM; Bonomo RA
    Antimicrob Agents Chemother; 2014; 58(4):1835-46. PubMed ID: 24379206
    [TBL] [Abstract][Full Text] [Related]  

  • 12. β-Lactamase inhibitors: what you really need to know.
    Ambrose PG; Lomovskaya O; Griffith DC; Dudley MN; VanScoy B
    Curr Opin Pharmacol; 2017 Oct; 36():86-93. PubMed ID: 29096172
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The antibiotic pipeline for multi-drug resistant gram negative bacteria: what can we expect?
    Falagas ME; Mavroudis AD; Vardakas KZ
    Expert Rev Anti Infect Ther; 2016 Aug; 14(8):747-63. PubMed ID: 27400643
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacologic optimization of antibiotics for Gram-negative infections.
    Gill CM; Nicolau DP
    Curr Opin Infect Dis; 2019 Dec; 32(6):647-655. PubMed ID: 31567737
    [TBL] [Abstract][Full Text] [Related]  

  • 15. What the Clinical Microbiologist Should Know About Pharmacokinetics/Pharmacodynamics in the Era of Emerging Multidrug Resistance: Focusing on β-Lactam/β-Lactamase Inhibitor Combinations.
    Abodakpi H; Wanger A; Tam VH
    Clin Lab Med; 2019 Sep; 39(3):473-485. PubMed ID: 31383269
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Repurposing Peptidomimetic as Potential Inhibitor of New Delhi Metallo-β-lactamases in Gram-Negative Bacteria.
    Liu Y; Yang K; Jia Y; Wang Z
    ACS Infect Dis; 2019 Dec; 5(12):2061-2066. PubMed ID: 31637907
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics-Pharmacodynamics of CB-618 in Combination with Cefepime, Ceftazidime, Ceftolozane, or Meropenem: the Pharmacological Basis for a Stand-Alone β-Lactamase Inhibitor.
    Ambrose PG; VanScoy BD; Trang M; McCauley-Miller J; Conde H; Bhavnani SM; Alexander DC; Friedrich LV
    Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28947474
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New β-Lactamase Inhibitors in the Clinic.
    Papp-Wallace KM; Bonomo RA
    Infect Dis Clin North Am; 2016 Jun; 30(2):441-464. PubMed ID: 27208767
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic/pharmacodynamic target attainment in critically ill renal patients on antimicrobial usage: focus on novel beta-lactams and beta lactams/beta-lactamase inhibitors.
    Gatti M; Pea F
    Expert Rev Clin Pharmacol; 2021 May; 14(5):583-599. PubMed ID: 33687300
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Spotlight on ceftazidime/avibactam: a new option for MDR Gram-negative infections.
    Falcone M; Paterson D
    J Antimicrob Chemother; 2016 Oct; 71(10):2713-22. PubMed ID: 27432599
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.